A Phase I Study to Assess the Safety of Pegcetacoplan (APL-2) as an Add-On to Standard of Care in Subjects With PNH
Completed
Apellis Pharmaceuticals, Inc.
Phase 1
2015-02-23
This study will be the initial exploration of pegcetacoplan in patients with PNH. The
assessments of the safety, tolerability, PK, and PD following administration of single and
multiples doses of pegcetacoplan will guide decisions to further develop the drug.
Assessment of Safety, Tolerability and Pharmacokinetics of Intravitreal Pegcetacoplan (APL-2) for Patients With Wet AMD
Completed
Apellis Pharmaceuticals, Inc.
Phase 1
2015-01-28
The objective of this study is to provide initial safety, tolerability and pharmacokinetics
information of intravitreal administration of pegcetacoplan in order to support further
development into larger Phase II studies for treatment of patients with AMD.
Study of Pegcetacoplan (APL-2) Therapy in Patients With Geographic Atrophy
Completed
Apellis Pharmaceuticals, Inc.
Phase 2
2015-09-24
The primary objectives of the study are to assess the safety, tolerability and evidence of
activity of multiple intravitreal (IVT) injections of pegcetacoplan in subjects with
Geographic Atrophy associated with Age-Related Macular Degeneration (AMD).
Pilot Study to Assess Safety, Preliminary Efficacy and Pharmacokinetics of S.C. Pegcetacoplan (APL-2) in PNH Subjects.
Completed
Apellis Pharmaceuticals, Inc.
Phase 1
2015-12-01
The objectives of the study are to assess the safety, tolerability, preliminary efficacy and
PK of multiple subcutaneous (SC) doses of pegcetacoplan in subjects with paroxysmal nocturnal
hemoglobinuria (PNH) who have not received treatment with eculizumab in the past.
An exploratory objective of the study is to assess the pharmacodynamics (PD) of multiple SC
doses of pegcetacoplan when administered to PNH patients.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
